TABLE 2.
Potential role of posaconazole against Candida albicans infections
| Type of infection | C. albicans isolate EUCAST classification | Posaconazole treatment | Comment |
|---|---|---|---|
| Noninvasive | Wild type (MIC, ≤0.06 mg/liter) | Oral | TDM (Cmin > 0.7 mg/liter)a |
| Non-wild type (low-level resistance MIC, 0.125 to 0.25 mg/liter) | Oral with or without i.v./tablet | TDM (Cmin > 2.4 mg/liter)b | |
| Non-wild type (MIC, >0.25 mg/liter) | None | ||
| Invasive | Wild type (MIC, ≤0.06 mg/liter) | i.v./tablet | TDM (Cmin > 0.7 mg/liter)a,b |
| Non-wild type (MIC, >0.06 mg/liter) | None |
a
Cmin > 1.4 mg/liter for CLSI24h method.
b
Consider combination therapy with an echinocandin in order to cover until the steady state is reached.